Evidence map›Paper›PMID 33966611›Full record

ReviewCell cycle (Georgetown, Tex.)2021

Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma.

Nicholas Barnaba, Jeannine R LaRocque

Open access · bronzeAbstract readReview
In one paragraph

Review in Cell cycle (Georgetown, Tex.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 79 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Transcriptomic analysis of Paraoxonase 1 expression in hepatocellular carcinoma and its potential impact on tumor immunity.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nicholas BarnabaBiology Department, Georgetown University, Washington, DC, USA.
Jeannine R LaRocqueDepartment of Human Science, Georgetown University, Washington, DC, USA.ORCID 0000-0002-1523-9677
Georgetown University · US

Funding

Mitotic DNA double-strand break repair in Drosophila melanogasterR15GM129628 · NIGMS · GEORGETOWN UNIVERSITY · PI LAROCQUE KAPPAS, JEANNINE · 2018 to 2018
$465k
NIGMS NIH HHS R15 GM129628
6 · The paper itself

Abstract

Disruption of cell cycle checkpoints has been well established as a hallmark of cancer. In particular, the G1-S transition mediated by the cyclin D-cyclin-dependent kinase 4/6 (CDK4/6) pathway is dysregulated in more than 90% of melanoma cases. Therefore, tumor cells mainly rely on the G2-M checkpoint to halt the cell cycle in order to repair DNA damage. Here, we review the promising method of cell cycle-mediated synthetic lethality for melanoma treatment, which entails exploiting somatically acquired mutations in the G1-S transition with inhibitors of the G2-M transition in order to specifically kill melanoma cells. The idea stems from the theory that melanoma cells lacking G1-S checkpoints are particularly vulnerable to mitotic catastrophe when presented with G2-M checkpoint inhibition in addition to DNA damage, whereas normal cells with intact G1-S checkpoints should theoretically be spared. This review explores the link between cell cycle dysregulation and synthetic lethality in melanoma cells and discusses potential future applications for this treatment.

Indexed as

AnimalsAntineoplastic AgentsCell Cycle CheckpointsCheckpoint Kinase 1DNA DamageG2 Phase Cell Cycle CheckpointsHumansImmune Checkpoint InhibitorsMelanomaSkin NeoplasmsSynthetic Lethal MutationsAntineoplastic AgentsCheckpoint Kinase 1CHEK1 protein, humanImmune Checkpoint Inhibitorscell cycle checkpointCHK1G1-S transitionG2-M transitionmelanomasynthetic lethalityWEE1

Identifiers

PMID33966611
PMCPMC8208119
OpenAlexW3160186015

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.